Editas Medicine announced on March 20, 2025, that Erick J. Lucera will step down as Chief Financial Officer, effective March 28, 2025, to pursue another opportunity. Amy Parison, who currently serves as Senior Vice President of Finance, has been appointed to succeed Mr. Lucera as CFO.
Ms. Parison joined Editas Medicine two and a half years prior as head of Finance, working closely with the outgoing CFO. Her experience includes financial decision-making, accounting acumen, and team leadership abilities, making her the internal choice for the role.
This transition occurs at a pivotal time for Editas Medicine as it focuses on becoming a fully in vivo gene editing company. Ms. Parison's prior experience includes roles at Rubius Therapeutics and Vertex Pharmaceuticals, as well as PricewaterhouseCoopers, LLP.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.